Compare VRA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRA | BTAI |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 36.5M |
| IPO Year | 2010 | 2018 |
| Metric | VRA | BTAI |
|---|---|---|
| Price | $2.61 | $1.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 158.1K | ★ 301.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $416,097,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | $261.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.39 | $1.17 |
| 52 Week High | $3.41 | $8.08 |
| Indicator | VRA | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 49.74 |
| Support Level | $1.89 | $1.50 |
| Resistance Level | $2.84 | $1.72 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 34.04 | 49.06 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.